---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-268815"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:51:11.725590+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kymera reports Q3 net loss $52.9M; initiates Phase 2 HS trial, receives $40M milestone

## Summary
- Net loss of $52.9M in Q3 2023 vs $43.0M loss in Q3 2022; revenue $4.7M down from $9.6M.
- First patient dosed in KT-474 (IRAK4) Phase 2 HS trial triggered $40M milestone from Sanofi; Phase 2 AD dosing expected Q4 2023.
- KT-333 (STAT3) Phase 1 shows partial response in CTCL patient; Fast Track granted for CTCL/PTCL.
- KT-253 (MDM2) achieved proof-of-mechanism; confirmed partial response in Merkel cell carcinoma patient.
- KT-413 (IRAKIMiD) development discontinued; cash $435M provides runway into H1 2026.

## SEC filing metadata
- accession: 0001193125-23-268815
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/0001193125-23-268815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/d579034d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-268815
- JSON: https://secwatch.observer/filing/0001193125-23-268815.json
- Plain text: https://secwatch.observer/filing/0001193125-23-268815.txt

## Key facts
- Earnings Releases
  Kymera Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.
  - Period: third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 2, 2023, Kymera Therapeutics, Inc. announced its financial results for the quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312523268815/0001193125-23-268815-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.